Medtronic, the US medical technology company, has announced that it will cooperate with the local diabetes management platform, Micro Sugar, to develop strategic cooperation around insulin pump therapy in the field of diabetes mobile medicine . Through the micro-sugar online community, patients can spend thousands of dollars to try Medtronic insulin pump for a period of time, and learn the skills of using insulin pump to control sugar under the guidance of professionals. At the same time, existing users of Medtronic insulin pumps will be able to obtain information on insulin pump therapy and the latest operating guidelines through the micro-sugar client on mobile devices such as smartphones. As a traditional medical company, Medtronic has also begun to pay attention to the "Internet +" direction in recent years. As early as 2013, it spent $200 million to acquire Cardiocom, a provider of remote heart disease management and patient monitoring services. "Internet + medical" is a new development direction of the medical industry in recent years. It is conducive to solving the contradiction between China's medical resource imbalance and people's increasing health care needs. It is also a medical service development model actively guided and supported by the Ministry of Health. As a traditional medical high-tech enterprise, Medtronic is constantly advancing in the direction of "Internet +". For example, in the face of China's surging mobile medical care and China's huge diabetes market, Medtronic has taken a positive step in China. Through cooperation with micro-sugar, it is expected to achieve patient data management, more effective patient education, and more accurate doctors. The combination of treatment options and higher quality online and offline services in a closed loop ecosystem. Annette Bruls, global vice president of Medtronic Diabetes Business Group, said: "Medtronic is globally focused on new opportunities brought about by mobile healthcare innovation. The partnership with Micro Sugar is the first attempt to develop mobile healthcare cooperation with local business partners in China. China has a global presence. The largest group of people with diabetes, the total number is close to 100 million, of which millions of patients rely on insulin therapy, and our cooperation with micro-sugar is aimed at improving the accessibility of insulin pump therapy through mobile medical means, so that more China 1 Patients with type 2 and type 2 diabetes benefit from this advanced therapy. At the same time, this collaboration will help existing Medtronic insulin pump patients get better operational guidance and after-sales service, and strengthen blood sugar self-management capabilities." Established in 2013, Micro Sugar is mainly engaged in diabetes management services inside and outside the hospital. It has two core apps, namely the “micro sugar†end used by sugar friends and the “micro sugar doctor†end used by professional medical staff. At present, there are 11,000 diabetes specialists contracted by micro-sugars nationwide, and the number of online users exceeds 700,000. "In the future, we will focus on the pains of patients and doctors around the various aspects of the hospital's out-of-hospital management, and develop an updated management model," said Feng Yanfei, founder and CEO of Micro Sugar. The insulin pump is a semi-automatic insulin input device that can control the input amount by preset. Compared with insulin pumps, conventional daily multiple injections of insulin therapy are prone to cause hypoglycemic events due to large differences in absorption and difficulty in precise control of doses. At the same time, traditional injection methods have greatly affected the quality of life of patients. Insulin pump therapy can simulate the normal working mode of the pancreas, provide continuous infusion of 24-hour insulin and insulin infusion during meals, get rid of the daily injections, and better control blood sugar levels and reduce the risk of diabetic complications. Medtronic is the largest supplier of insulin pumps to the global and Chinese market. Since entering China for 16 years, it has served more than 500,000 patients, including type I and type II diabetes.
Resistance to bacterial,Yohimbine Hydrochloride,Sodium Picosulfate Toxicity,Sodium Picosulfate Powder,Buy Online Cinchonine,
It is a professional supplier of Antibiotic & Antibacterial Product Raw Material,Beta Cyclodextrin Powder and natural active ingredients. It has absolute advantage because of strong research strength, modern management system and high-quality marketing team.
Resistance to bacterial,Yohimbine Hydrochloride,Sodium Picosulfate Toxicity,Sodium Picosulfate Powder,Buy Online Cinchonine Xi'an Henrikang Biotech Co.,Ltd , https://www.henrikangbio.com
Now we have 3 GMP standard workshop, Meanwhile, the factory is equipped with the researching and quality inspection centre, with strong technology research and development strength. We also have 3 salesdepartments over 30 people and sell our products all over the world.
For customer`s needs, OEM service is also acceptable. If you have a good idea in new product production but lack of laboratory device and human resource, we are glad to solve this problem for you. Sincerely hope to strengthen exchanges and cooperation with friends from both home and abroad.